BALPHARMA.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Stats
Šios dienos apimtis	8 865.00
Vidutinė apimtis	47 625.00
Rinkos kapitalizacija	1.59B
EPS	INR0 ( 2024-02-11 )
Kita pelno data	( INR0 ) 2024-05-27
Last Dividend	INR1.000 ( 2023-09-18 )
Next Dividend	INR0 ( N/A )
P/E	45.38
ATR14	INR0.136 (0.14%)

Tūris Koreliacija

Ilgas: -0.15 (neutral)

Trumpas: 0.37 (neutral)

Signal:(51.148) Neutral

Bal Pharma Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
EMIL.NS	0.925
INDIGOPNTS.NS	0.921
MEDICAMEQ.NS	0.921
GOCOLORS.NS	0.92
NAVNETEDUL.NS	0.919
SABEVENTS.NS	0.916
ASAHISONG.NS	0.915
MCLEODRUSS.NS	0.912
SGL.NS	0.91
IGPL.NS	0.91

10 Labiausiai neigiamai susiję koreliacijos
RAJRILTD.NS	-0.92
4THDIM.NS	-0.915
LTGILTBEES.NS	-0.898
ISMTLTD.NS	-0.889
GNA.NS	-0.865
KAYNES.NS	-0.865
JINDCOT.NS	-0.858
KIRLFER.NS	-0.852
SYMPHONY.NS	-0.85
SHRIRAMEPC.NS	-0.846

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Bal Pharma Limited Koreliacija - Valiuta/Žaliavos

-0.34
( neutral )

-0.54
( weak negative )

0.00
( neutral )

-0.60
( weak negative )

-0.10
( neutral )

0.70
( moderate )

Bal Pharma Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR3.04B
Bruto pelnas:	INR1.31B (43.21 %)
EPS:	INR1.640

FY	2022
Pajamos:	INR3.04B
Bruto pelnas:	INR1.31B (43.21 %)
EPS:	INR1.640

FY	2022
Pajamos:	INR2.81B
Bruto pelnas:	INR1.11B (39.64 %)
EPS:	INR3.79

FY	2021
Pajamos:	INR2.51B
Bruto pelnas:	INR993.03M (39.64 %)
EPS:	INR3.34

Financial Reports:

No articles found.

Bal Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR1.000 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.000 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Bal Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 1.444 - low (50.00%) | Divividend Growth Potential Score: 2.52 - Decrease likely (49.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.750	2006-09-07
Last Dividend	INR1.000	2023-09-18
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	14	--
Total Paid Out	INR13.00	--
Avg. Dividend % Per Year	0.69%	--
Score	1.51	--
Div. Sustainability Score	1.444
Div.Growth Potential Score	2.52
Div. Directional Score	1.982	--

Next Divdend (Est)
(2024-11-07)

INR1.018 Estimate 2.97 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.51

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.000	1.18%
2019	INR1.000	1.27%
2020	INR0	0.00%
2021	INR1.000	1.78%
2022	INR1.000	0.79%
2023	INR1.000	1.09%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUPRIYA.NS	Dividend Junior	2023-09-15	Annually	3	0.10%
NCLIND.NS	Dividend Junior	2023-09-15	Semi-Annually	18	1.25%
ICEMAKE.NS	No Dividend Player	2023-09-14	Annually	7	0.81%
CDSL.NS	Dividend Junior	2023-08-25	Annually	7	0.92%
RPPL.NS	Dividend Junior	2023-08-24	Annually	6	0.31%
LIKHITHA.NS	Dividend Junior	2023-09-20	Annually	4	0.46%
GANESHHOUC.NS	Dividend Junior	2023-08-31	Sporadic	18	0.18%
APTUS.NS	Dividend Junior	2023-05-12	Semi-Annually	3	0.32%
TECHNOE.NS	Dividend Junior	2023-09-15	Annually	16	1.13%
ONGC.NS	Dividend Knight	2023-08-18	Semi-Annually	28	4.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0142	1.500	9.72	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0729	1.500	-0.301	-0.451	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.455	1.000	-0.572	-0.572	[3 - 30]
operatingCashFlowPerShareTTM	12.66	2.00	5.78	10.00	[0 - 30]
freeCashFlowPerShareTTM	12.66	2.00	3.67	7.34	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.440	1.000	6.00	6.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.0666	1.000	-0.667	-0.667	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.444

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	34.24	1.000	6.64	0	[1 - 100]
returnOnEquityTTM	0.0729	2.50	-0.193	-0.451	[0.1 - 1.5]
freeCashFlowPerShareTTM	12.66	2.00	5.78	7.34	[0 - 30]
dividendYielPercentageTTM	0.997	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	12.66	2.00	5.78	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.604	1.500	-7.36	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0612	1.000	-0.970	0	[0.1 - 0.5]
Total Score				2.52

Bal Pharma Limited

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.